RecruitingEarly Phase 1NCT07261306
Comparison Between Oral Methotrexate and Tofacitinib in Chronic Plaque Psoriasis
Sponsor
Lahore General Hospital
Enrollment
75 participants
Start Date
Aug 29, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
Psoriasis is a chronic inflammatory dermatoses which include well demarcated scaly erythematous plaques on whole body including scalp role of methotrexate vs tofacitinib is compared in this study
Eligibility
Min Age: 18 YearsMax Age: 70 Years
Inclusion Criteria4
- Patients aged 18- 70 years of either gender.
- Only patients with Psoriasis Area and Severity Index (PASI) score of 10 or above, and/or Body Surface Area (BSA) involvement of 10% or more, will be included.
- Duration of plaque psoriasis for at least 6 months prior to the study.
- Psoriasis that has not shown adequate response to topical therapies
Exclusion Criteria5
- Individuals with other forms of psoriasis or other significant dermatological conditions that might interfere with the assessment of psoriasis.
- Participants currently receiving systemic corticosteroids, biologics, or any other immunosuppressive agents within 4 weeks prior to the start of the study will be excluded.
- Known hypersensitivity or contraindications to either methotrexate or tofacitinib.
- History of significant liver, kidney, hematologic/bleeding disorder, gastrointestinal/acid peptic disease, or immune system disorders.and any history of tuberculosis and malignancy.
- Pregnant or lactating women will not be eligible for the study.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGMethotrexate
Methotrexate is an antifolate drug work by inhibiting enzyme dihydrofolate reductase and inhibit cell proliferation and play a role in psoriasis treatment
DRUGTofacitinib
Tofacitinib is janus kinase inhibitor and have role in psoriasis
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07261306
Related Trials
Metabolic Profiling of Immune Responses in Immune-mediated Diseases
NCT048648861 location
Cytokine Expression in Psoriasis Patients With and Without Joint Involvement
NCT053078091 location
Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors
NCT047513961 location
A Real-world Study to Evaluate the Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in France (RePhlect)
NCT0670151348 locations
A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
NCT0685794241 locations